139290-68-9

Upstream product

• 498-94-2 isonipecotic acid 
• 332-42-3 (2-bromoethyl)-4-fluorobenzene 
• 139290-67-8 4-cyano-1-[2-(4-fluorophenyl)ethyl]piperidine 

Downstream Products

• 139290-67-8 4-cyano-1-[2-(4-fluorophenyl)ethyl]piperidine 

Relevant academic research and scientific papers

COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF

The invention concerns the combination of a short-acting hypnotic agent and R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (Compound A) or its prodrug having the Formula II: wherein R is C1-C20 alkyl o

Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis

The present invention is directed to use of (+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug (Formula II) in treating patients for symptoms of dementia and dopamine induced psychosis.

USE OF R-(+)-alpha-(2,3-DIMETHOXYPHENYL-1-[2-(4-FLUOROPHENYL) ETHYLl-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

A method of treating a patient for a Sleep Disorder comprising administering an effective amount of R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

Use of (+)- alpha -(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders

The present invention is directed to the use of (+)- alpha -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol in treating Depressive Disorders and Bipolar Disorders.

Esters of (+)- alpha -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol

The present invention is directed to esters of (+)- alpha -(2,3 Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.

Treatment of obsessive-compulsive disorders with 5-HT2 antagonists

The present invention is directed to 5-HT2 antagonists and their use as agents in the treatment of obsessive-compulsive disorders (OCD). The invention is particularly directed to the compound (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)eth

(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol

The present invention is directed to a new 5HT2 antagonist, (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, and its use in the treatment of a number of disease states.